ARCHIVES

FDA unlikely to pull Iressa from market. Iressa a case study in how not to develop a drug, ODAC member says.

This article is from The Cancer Letter archive.

Vol. 31 No. 13 | April 1, 2005

Download PDF Visit The Full Archive

Related Articles

Holland, Hoogstraten Give Up Chairmanships Of CALGB, SWOG

March 6, 1981

NCI to Close Clinical Branch at Frederick, Move Patients, Protocols To Bethesda

May 17, 1996

WHI Investigators Reiterate: Breast Cancer, CHD Risks Too Great For Routine HT Use

November 2, 2002

NSABP Executive Committee Nominates Wolmark To Succeed Fisher As Chairman

October 21, 1994

Also in this 8-page issue: Cooperative groups tell Congress that NCI’s $115 million in support for adult cancer clinical trials is “chump change.” Trials would close faster, report results sooner, if funding were increased, regulatory issues streamlined.

May 28, 2004

In Brief: NCAB Appointments: Boutwell Stay On; Brown, Elion, Strong, Korn Named; One Vacancy Remains

May 18, 1984